PreferaOB + DHA Rx
Generic Name and Formulations:
Thiamine 1.5mg, riboflavin 1.6mg, niacinamide 17mg, pantothenic acid 10mg, pyridoxine 50mg, folic acid 1mg, Vit. B12 12mcg, biotin 30mcg, Vit. D3 400 IU, Vit. E 10 IU, iodine (as potassium iodide) 250mcg, iron (polysaccharide iron complex 28mg + heme iron polypeptide as Proferrin 6mg), copper (as cupric sulfate) 0.8mg, selenium (as sodium selenate) 65mcg, zinc (as oxide) 4.5mg; tabs. Docosahexaenoic acid (DHA, plant-based [microalgae]) 200mg; softgels.
Indications for PreferaOB + DHA:
Nutritional supplement during pregnancy, prenatal, and postnatal periods.
1 tab and 1 DHA softgel daily.
Wilson's disease. Hemochromatosis. Treatment of pernicious or other megaloblastic anemias.
Folic acid may mask pernicious anemia. DHA: bleeding diatheses.
Iron blocks tetracycline absorption. Antagonizes levodopa. DHA: avoid anticoagulants.
PreferaOB—90; PreferaOB + DHA (30 tabs + 30 softgels)—60; PreferaOB ONE—30
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds